HAVCR2 and glioma: As such, we tested the anti-TIM3 agent in 2 preclinical models including a low-grade glioma GEMM model driven by PDGF and subsequent MAPK activation (48–53, 69) and a standard clonotype high-grade glioma, CT-2A.